新型直接口服抗凝药物与胃肠道出血的研究进展
发布时间：2019-04-20 17:18
【摘要】：2010年,一类新型直接口服抗凝药(DOAC)被批准用于非瓣膜性心房颤动患者预防血栓性脑卒中及治疗静脉血栓栓塞症(VTE)/肺栓塞(PE)。与传统口服抗凝药维生素K拮抗剂(VKA)相比,DOAC的抗凝效果确切,安全性更好、服用更方便,且更少引起颅内出血事件,但可能会增加胃肠道的出血风险。由于DOAC的半衰期短,大多数胃肠道出血无需特殊处理,但在出血危及生命或急诊手术时需给予逆转剂抵抗DOAC的抗凝作用。本文旨在对DOAC相关胃肠道出血的发生率、预防治疗及DOAC特异性逆转剂等作一综述。
[Abstract]:In 2010, a new type of direct oral anticoagulant (DOAC) was approved for the prevention of thrombotic stroke and the treatment of (VTE) / pulmonary embolism (PE). In patients with non-valvular atrial fibrillation Compared with traditional oral anticoagulant vitamin K antagonist (VKA), DOAC has better anticoagulation effect, better safety, more convenient use and fewer intracranial bleeding events, but it may increase the risk of gastrointestinal bleeding. Due to the short half-life of DOAC, most gastrointestinal bleeding does not require special treatment, but reverse agents should be given to resist the anticoagulant effect of DOAC when bleeding is life-threatening or emergency operation. The purpose of this review is to review the incidence of DOAC-related gastrointestinal bleeding, prevention and treatment, and DOAC-specific reversal agents.
【作者单位】： 第二军医大学长海医院消化内科;
【分类号】：R973.2
本文编号：2461799
[Abstract]:In 2010, a new type of direct oral anticoagulant (DOAC) was approved for the prevention of thrombotic stroke and the treatment of (VTE) / pulmonary embolism (PE). In patients with non-valvular atrial fibrillation Compared with traditional oral anticoagulant vitamin K antagonist (VKA), DOAC has better anticoagulation effect, better safety, more convenient use and fewer intracranial bleeding events, but it may increase the risk of gastrointestinal bleeding. Due to the short half-life of DOAC, most gastrointestinal bleeding does not require special treatment, but reverse agents should be given to resist the anticoagulant effect of DOAC when bleeding is life-threatening or emergency operation. The purpose of this review is to review the incidence of DOAC-related gastrointestinal bleeding, prevention and treatment, and DOAC-specific reversal agents.
【作者单位】： 第二军医大学长海医院消化内科;
【分类号】：R973.2
【相似文献】
相关期刊论文 前4条
1 邵泽勇;辛建;;肿瘤细胞多药耐药化学逆转剂研究进展[J];中外医疗;2008年22期
2 华英;胡人杰;;ATP结合盒转运蛋白介导的MDR逆转剂的实验研究现况[J];天津药学;2006年06期
3 张肃,梁钢;肿瘤多药耐药性及其逆转剂研究进展[J];中国药理学通报;2002年06期
4 迟文俊,李爱华,迪丽达尔;肿瘤多药耐药性逆转剂的研究新进展[J];中国基层医药;2004年01期
相关会议论文 前1条
1 刘晓东;刘国卿;;MDR逆转剂与血脑屏障上的P-糖蛋白ATP酶相互作用[A];中国药理学会第九届制药工业药理学术会议论文摘要汇编[C];2000年
，本文编号：2461799
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2461799.html
最近更新
教材专著
